Abstract 12706: Carotid Plaque Lipid Content is Reduced After 6 Months of Proprotein Convertase Subtilisin Kexin Type 9 Inhibition With Alirocumab: an Interim Analysis of a Serial Magnetic Resonance Imaging Study

Introduction: In the ODYSSEY OUTCOMES trial, proprotein convertase subtilisin kexin type 9 inhibition (PCSK9i) with alirocumab reduced recurrent major cardiovascular events by 15%, including 27% in...